New drug trial aims to outperform standard treatment for advanced breast cancer

NCT ID NCT06265428

Summary

This study is testing whether a new drug called DB-1303 works better and is as safe as the current treatment, T-DM1, for people with advanced HER2-positive breast cancer that has spread or cannot be removed by surgery. The trial will involve about 224 adults whose cancer has progressed despite prior treatment with trastuzumab and a taxane chemotherapy. Participants will be randomly assigned to receive either the new drug or the standard treatment to directly compare their effectiveness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • 001

    Beijing, Beijing Municipality, 100039, China

  • 002

    Shanghai, Shanghai Municipality, 200032, China

  • 003

    Xi’an, Shanxi, 710061, China

  • 004

    Nanjing, Jiangsu, 210029, China

  • 005

    Zhengzhou, Henan, 450052, China

  • 006

    Zhengzhou, Henan, 450003, China

  • 007

    Chengdu, Sichuan, 610041, China

  • 008

    Changchun, Jilin, 130021, China

  • 009

    Wuhan, Hubei, 430079, China

  • 010

    Beijing, Beijing Municipality, 100142, China

  • 011

    Wuhan, Hubei, 430030, China

  • 012

    Linyi, Shandong, 276003, China

  • 013

    Ürümqi, Xinjiang, 830011, China

  • 014

    Nanchang, Jiangxi, 330006, China

  • 015

    Bengbu, Anhui, 233000, China

  • 016

    Hefei, Anhui, 230001, China

  • 017

    Nanning, Guangxi, 530021, China

  • 018

    Luoyang, Henan, 471003, China

  • 019

    Hangzhou, Zhejaing, 310022, China

  • 020

    Haerbin, Heilongjiang, 150081, China

  • 021

    Tianjin, Tianjin Municipality, 300060, China

  • 022

    Nanning, Guangxi, 530021, China

  • 023

    Guangzhou, Guangdong, 510060, China

  • 024

    Guangzhou, Guangdong, 510080, China

  • 025

    Hangzhou, Zhejiang, 310003, China

  • 026

    Guangzhou, Guangdong, 510120, China

  • 027

    Nanjing, Jiangsu, 210009, China

  • 028

    Huizhou, Guangdong, 516001, China

  • 029

    Hefei, Anhui, 230601, China

  • 030

    Changsha, Hunan, 410005, China

  • 031

    Jinan, Shandong, 250013, China

  • 032

    Dalian, Liaoning, 116021, China

  • 033

    Kunming, Yunnan, 650118, China

  • 034

    Yibin, Sichuan, 644000, China

  • 035

    Taiyuan, Shanxi, 030013, China

  • 036

    Fuzhou, Fujian, 350014, China

  • 037

    Xiamen, Fujian, 361003, China

  • 038

    Jilin, Changchun, 130022, China

  • 039

    Yantai, Shandong, 264001, China

  • 040

    Binzhou, Shandong, 256603, China

  • 041

    Neijiang, Sichuan, 641100, China

  • 042

    Hangzhou, Zhejiang, 310016, China

  • 043

    Haikou, Hainan, 570102, China

  • 044

    Xuzhou, Jiangsu, 221006, China

  • 045

    Baoding, Hebei, 071000, China

  • 046

    Shanghai, Shanghai Municipality, 200120, China

  • 047

    Jinan, Shandong, 250117, China

  • 048

    Shijiazhuang, Hebei, 050011, China

Conditions

Explore the condition pages connected to this study.